Escitalopram Therapy for Major Depression and Anxiety Disorders

@article{Baldwin2007EscitalopramTF,
  title={Escitalopram Therapy for Major Depression and Anxiety Disorders},
  author={D. Baldwin and E. Reines and C. Guiton and E. Weiller},
  journal={Annals of Pharmacotherapy},
  year={2007},
  volume={41},
  pages={1583 - 1592}
}
Background: Randomized controlled clinical trials have demonstrated that escitalopram is efficacious in a range of mood and anxiety disorders, but the individual trials are insufficiently large to allow a full exploration of its tolerability. Objective: To assess (he tolerability and safety of escitalopram through analysis of all randomized controlled clinical trials in major depressive disorder and anxiety disorders. Methods: Analyses of tolerability were based on data from all available… Expand
[Efficacy and tolerability of escitalopram in anxiety disorders: a review].
TLDR
Clinical data indicate that escitalopram, 10-20 mg/d, is an effective and well-tolerated first-line option for the management of panic disorder, GAD, social anxiety and OCD, and continued efficacy in a 24-week extension study of short double-blind trials and in a placebo-controlled, double- blind, 24/76-week relapse-prevention study. Expand
Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo
TLDR
In this meta-analysis, all doses of escitalopram showed significant superiority in efficacy versus placebo in the treatment of patients with SAD. Expand
Comparative efficacy of escitalopram in the treatment of major depressive disorder
  • M. Ali, R. Lam
  • Medicine
  • Neuropsychiatric disease and treatment
  • 2011
TLDR
Based on pooled and meta-analysis studies, escITALopram demonstrates superior efficacy compared with citalopram and with SSRIs combined, especially in more severely depressed patients. Expand
Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study
TLDR
The study suggests that escITALopram 10–20 mg/d are as effective and safe as citalopram 20–40 mg /d in the short-term treatment for Chinese MDD patients. Expand
Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders
  • R. Lam, L. Annemans
  • Medicine
  • Expert review of pharmacoeconomics & outcomes research
  • 2007
TLDR
Escitalopram has a prominent role in the treatment of major depressive disorder and anxiety disorders, and may also prove to be important in the Treatment of mixed depressive anxiety disorder. Expand
Efficacy of escitalopram monotherapy in the treatment of major depressive disorder
TLDR
Escitalopram monotherapy is effective and safe in the treatment of major depressive disorder in Chinese patients, and therapeutic efficacy is dependent on the severity of MDD. Expand
Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study
TLDR
Escitalopram, either as monotherapy or an augmentative treatment, was found to be well tolerated in a large sample of patients with affective disorders, with an overall low rate of side effects. Expand
Escitalopram for the treatment of major depression and anxiety disorders
TLDR
Compared with other antidepressants, escitalopram is generally better tolerated, its onset of action is relatively fast, and its use may have cost–effectiveness and cost–utility advantages. Expand
Clinical Features and Efficacy of Escitalopram Treatment for Geriatric Depression
TLDR
Depressed geriatric patients were found to have abnormal personality traits, and escitalopram was efficacious and had a good safety profile in the treatment of geriatric depression. Expand
Escitalopram And Mirtazapine For The Treatment Of Depression In Hiv Patients: A Randomized Controlled Open Label Trial
Objective: The objective of this study was to compare the safety and efficacy of mirtazapine and escitalopram in HIV patients for the treatment of depression. Methods: In this trial, 70 adult HIVExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 108 REFERENCES
Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials.
TLDR
Results from the individual trials and the pooled analysis demonstrate that escitalopram is effective and well tolerated for the treatment of GAD. Expand
Escitalopram in the treatment of generalized anxiety disorder: Double‐blind, placebo controlled, flexible‐dose study
TLDR
The escitalopram group showed a statistically significant, and clinically relevant, greater improvement at endpoint compared with placebo in all prospectively defined efficacy parameters, and was well tolerated in the treatment of patients with GAD. Expand
Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
TLDR
Evaluating the safety and efficacy of escitalopram in outpatients diagnosed with panic disorder found it efficacious, safe, and well tolerated in the treatment of panic disorder. Expand
Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial*
TLDR
No differences in efficacy were observed for fixed-dose escitalopram 10 mg/day and sertraline flexibly dosed from 50–200  mg/day, and both treatments were generally well tolerated. Expand
Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
Abstract Escitalopram, a selective serotonin reuptake inhibitor (SSRI), was compared to placebo in a study of patients with major depressive disorder (DSM-IV) who had baseline Montgomery-AsbergExpand
Escitalopram in the treatment of depressed elderly patients.
TLDR
This was a "failed study" (i.e., neither active treatment was superior to placebo), and the efficacy results should, therefore, be interpreted with caution. Expand
Escitalopram in major depressive disorder: a multicenter, randomized, double‐blind, fixed‐dose, parallel trial in a Chinese population
Escitalopram, the S‐enantiomer of citalopram and the most selective of the selective serotonin reuptake inhibitor (SSRI) has been shown to be efficacious in the treatment of major depression in whiteExpand
Escitalopram and paroxetine in the treatment of generalised anxiety disorder
TLDR
Escitalopram was efficacious in generalised anxiety disorder, 20 was not significantly superior to 10 mg/day, and 10 mg was more efficacious thanParoxetine was superior to placebo on some secondary measures, at sometime points. Expand
Escitalopram in the treatment of social anxiety disorder
TLDR
EscITALopram was efficacious and well tolerated in the treatment of generalised social anxiety disorder and was supported by significant reduction in the work and social components of the Sheehan Disability Scale and by the good tolerability of escitalopram treatment. Expand
The onset of effect for escitalopram and its relevance for the clinical management of depression
TLDR
Onset of treatment response at 2 weeks is an important indicator of subsequent remission at 8 weeks and it would be a reasonable clinical recommendation that if patients fail to show a measurable clinical improvement within 2 weeks, a dose increase should be considered at this time. Expand
...
1
2
3
4
5
...